Constellation Pharmaceuticals, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Constellation Pharmaceuticals, Inc. (“Constellation” or the “Company”) (NASDAQ: CNST) in connection with the proposed acquisition of the Company by MorphoSys AG (“MorphoSys”) (FSE: MOR; NASDAQ: MOR). The transaction is structured as an all-cash tender offer pursuant to which the Company’s shareholders will receive $34.00 for each share of Constellation common stock that they hold.

WeissLaw LLP is investigating whether Constellation’s board acted in the best interest of Constellation’s public shareholders in agreeing to the proposed transaction, whether the $34.00 offer price adequately compensates Constellation’s shareholders, and whether all information regarding the process undertaken by the board and the valuation of the transaction will be fully and fairly disclosed to Constellation’s public shareholders. Notably, multiple analysts set price targets for Constellation above the offer price, with a high target of $75.00.

WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at stockinfo@weisslawllp.com

‍

Other Cases

January 23, 2024

Inhibrx, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Inhibrx, Inc. (“Inhibrx” or the “Company”)(NASDAQ: INBX), in connection with its acquisition by Aventis Inc. Under the merger agreement, the Company’s shareholders will receive: (i) $30.00 per share; (ii) one contingent value right (“CVR”) per share, representing the right to receive a contingent payment of $5.00 in cash upon the achievement of a regulatory milestone; and (iii) one SEC-registered, publicly listed, share of New Inhibrx per every four shares of Inhibrx common stock held.

Join Case →

January 16, 2024

Carrols Restaurant Group, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Carrols Restaurant Group, Inc. (“Carrols” or the “Company”) (NASDAQ: TAST), in connection with its acquisition by Restaurant Brands International Inc. (NYSE: QSR). Under the merger agreement, the Company’s shareholders will receive $9.55 per share. The transaction is valued at approximately $1.0 billion.

Join Case →

January 10, 2024

Juniper Networks, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Juniper Networks, Inc. (“Juniper” or the “Company”) (NYSE: JNPR), in connection with its acquisition by Hewlett Packard Enterprise Company (NYSE: HPE). Under the merger agreement, the Company’s shareholders will receive $40.00 per share. The transaction is valued at approximately $14 billion.

Join Case →